Showing posts with label bevacizumab and erlotinib NSCLC maintenance therapy. Show all posts
Showing posts with label bevacizumab and erlotinib NSCLC maintenance therapy. Show all posts
Tuesday, December 10, 2013

Toxicity limits benefits of bevacizumab–erlotinib NSCLC maintenance therapy

›
In continuation of my update on  bevacizumab and erlotinib  Two targeted anticancer drugs used together after first-line chemother...